Engineering One-Signal Activated TILs with CD3ζ-CD28 Chimeras Optimizes the Antitumor Efficacy of TIL-Based Immunotherapy
Yongqiang Wu, Xueshuai Ye, Yufeng Zhu, Shengchao Liu, Jiabao Song, Yutong Zhang, Qichen Yuan, Fei Liu, Dejing Kong, Lianmei Zhao
This paper engineers one-signal-activated TILs with CD3ζ-CD28 chimeras to enhance antitumor efficacy in immunotherapy.
bioRxiv · Mar 21, 2024 · PreprintImmunology